Trial · NCT01439880
Adverse events1,840
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,840
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhoea | Gastrointestinal disorders | SOC-controlled Period: SOC | 11 | 442 | |
| other | Diarrhoea | Gastrointestinal disorders | SOC-controlled Period: Evolocumab + SOC | 41 | 882 | |
| other | Diarrhoea | Gastrointestinal disorders | All-IP Period: SOC / Evolocumab | 33 | 398 | |
| other | Diarrhoea | Gastrointestinal disorders | All-IP Period: Evolocumab + SOC / Evolocumab | 61 | 822 | |
| other | Diarrhoea | Gastrointestinal disorders | All-IP Period: Total | 94 | 1,220 | |
| other | Gastrooesophageal reflux disease | Gastrointestinal disorders | SOC-controlled Period: SOC | 13 | 442 | |
| other | Gastrooesophageal reflux disease | Gastrointestinal disorders | SOC-controlled Period: Evolocumab + SOC | 23 | 882 | |
| other | Gastrooesophageal reflux disease | Gastrointestinal disorders | All-IP Period: SOC / Evolocumab | 20 | 398 | |
| other | Gastrooesophageal reflux disease | Gastrointestinal disorders | All-IP Period: Evolocumab + SOC / Evolocumab | 32 | 822 | |
| other | Gastrooesophageal reflux disease | Gastrointestinal disorders | All-IP Period: Total | 52 | 1,220 | |
| other | Nausea | Gastrointestinal disorders | SOC-controlled Period: SOC | 4 | 442 | |
| other | Nausea | Gastrointestinal disorders | SOC-controlled Period: Evolocumab + SOC | 23 | 882 | |
| other | Nausea | Gastrointestinal disorders | All-IP Period: SOC / Evolocumab | 23 | 398 | |
| other | Nausea | Gastrointestinal disorders | All-IP Period: Evolocumab + SOC / Evolocumab | 32 | 822 | |
| other | Nausea | Gastrointestinal disorders | All-IP Period: Total | 55 | 1,220 | |
| other | Fatigue | General disorders | SOC-controlled Period: SOC | 5 | 442 | |
| other | Fatigue | General disorders | SOC-controlled Period: Evolocumab + SOC | 31 | 882 | |
| other | Fatigue | General disorders | All-IP Period: SOC / Evolocumab | 16 | 398 | |
| other | Fatigue | General disorders | All-IP Period: Evolocumab + SOC / Evolocumab | 43 | 822 | |
| other | Fatigue | General disorders | All-IP Period: Total | 59 | 1,220 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01439880/events